Radioembolization with 166Ho microspheres induced a tumor response with an acceptable toxicity profile in patients with liver metastases.
Featured product: QuiremSpheres® Microspheres
Main Findings HEPAR 2 study:
38 Patients with unresectable liver metastases of any primary origin, who were unable to undergo systemic treatment were eligible. The main primary malignancies were colorectal (61%), breast (11%), cholangiocarcinoma (11%), neuroendocrine tumor (5%) and uveal melanoma (5%).
Single radioembolization with 166Ho polylactic microspheres, administered via the hepatic artery. The projected average absorbed dose was 60 Gy to the liver (equal to 3.8 GBq/kg liver tissue).
Response 3 months after 166Ho radioembolization
Number of patients (percentage of total).
* Not evaluable and/or missing patients classified as progressive disease
Study results have been published in PhD thesis of J.F. Prince; ISBN 978-90-393-6489-5; 2016. Publication in peer-reviewed journal is expected soon.
ClinicalTrials.gov Identifier: NCT01612325
This is HCP only content